Organogenesis Hldgs Analyst Ratings
Organogenesis Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 9.09% | Morgan Stanley | $5 → $3 | Maintains | Equal-Weight |
| 08/10/2023 | 45.45% | BTIG | $10 → $4 | Maintains | Buy |
| 06/15/2023 | 81.82% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 05/24/2023 | 263.64% | BTIG | → $10 | Upgrades | Neutral → Buy |
| 11/10/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 11/10/2021 | 627.27% | SVB Leerink | $26 → $20 | Maintains | Outperform |
| 08/10/2021 | 809.09% | Credit Suisse | $24 → $25 | Maintains | Outperform |
| 05/11/2021 | 845.45% | SVB Leerink | $27 → $26 | Maintains | Outperform |
| 03/17/2021 | 700% | SVB Leerink | $19 → $22 | Maintains | Outperform |
| 01/20/2021 | 372.73% | SVB Leerink | $10 → $13 | Maintains | Outperform |
| 01/07/2021 | 227.27% | Credit Suisse | $8 → $9 | Maintains | Outperform |
| 11/18/2020 | 263.64% | SVB Leerink | $9 → $10 | Maintains | Outperform |
| 11/10/2020 | 190.91% | Credit Suisse | $7 → $8 | Maintains | Outperform |
| 08/11/2020 | 227.27% | SVB Leerink | $7 → $9 | Maintains | Outperform |
| 05/12/2020 | 154.55% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 04/09/2020 | 190.91% | BTIG | $9 → $8 | Maintains | Buy |
| 01/10/2020 | 227.27% | SVB Leerink | → $9 | Initiates Coverage On | → Outperform |
| 08/26/2019 | — | Credit Suisse | Reinstates | → Outperform | |
| 05/02/2019 | 227.27% | Credit Suisse | → $9 | Initiates Coverage On | → Outperform |
| 04/17/2019 | 300% | Oppenheimer | → $11 | Initiates Coverage On | → Outperform |
| 04/12/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 04/11/2019 | 300% | SunTrust Robinson Humphrey | → $11 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月11日 | 9.09% | 摩根士丹利 | $5→$3 | 维护 | 等重 |
| 2023年08月10日 | 45.45% | BTIG | $10→$4 | 维护 | 买 |
| 2023/06/15 | 81.82% | 摩根士丹利 | →$5 | 开始承保 | →等重 |
| 2023年05月24日 | 263.64% | BTIG | →$10 | 升级 | 中性→购买 |
| 2022年11月10日 | - | BTIG | 评级下调 | 购买→中性 | |
| 2021年11月10日 | 627.27% | SVB Leerink | $26→$20 | 维护 | 跑赢大盘 |
| 2021/08/10 | 809.09% | 瑞士信贷 | $24→$25 | 维护 | 跑赢大盘 |
| 2021/11/05 | 845.45% | SVB Leerink | $27→$26 | 维护 | 跑赢大盘 |
| 03/17/2021 | 700% | SVB Leerink | $19→$22 | 维护 | 跑赢大盘 |
| 01/20/2021 | 372.73% | SVB Leerink | $10→$13 | 维护 | 跑赢大盘 |
| 01/07/2021 | 227.27% | 瑞士信贷 | $8→$9 | 维护 | 跑赢大盘 |
| 11/18/2020 | 263.64% | SVB Leerink | $9→$10 | 维护 | 跑赢大盘 |
| 11/10/2020 | 190.91% | 瑞士信贷 | $7→$8 | 维护 | 跑赢大盘 |
| 2020年08月11日 | 227.27% | SVB Leerink | $7→$9 | 维护 | 跑赢大盘 |
| 2020/05/12 | 154.55% | SVB Leerink | $8→$7 | 维护 | 跑赢大盘 |
| 04/09/2020 | 190.91% | BTIG | $9→$8 | 维护 | 买 |
| 2020/10/01 | 227.27% | SVB Leerink | →$9 | 开始承保 | →跑赢大盘 |
| 2019年08月26日 | - | 瑞士信贷 | 恢复 | →跑赢大盘 | |
| 2019年05月02日 | 227.27% | 瑞士信贷 | →$9 | 开始承保 | →跑赢大盘 |
| 2019/04/17 | 百分之三百 | 奥本海默 | →$11 | 开始承保 | →跑赢大盘 |
| 2019年4月12日 | - | BTIG | 开始承保 | →购买 | |
| 2019年4月11日 | 百分之三百 | SunTrust Robinson Humphrey | →$11 | 开始承保 | →购买 |
What is the target price for Organogenesis Hldgs (ORGO)?
有机生成Hldgs(Orgo)的目标价格是多少？
The latest price target for Organogenesis Hldgs (NASDAQ: ORGO) was reported by Morgan Stanley on August 11, 2023. The analyst firm set a price target for $3.00 expecting ORGO to rise to within 12 months (a possible 9.09% upside). 5 analyst firms have reported ratings in the last year.
有机生成Hldgs(纳斯达克代码：ORGO)的最新目标价是由摩根士丹利在2023年8月11日报道的。这家分析公司将目标价定为3.00美元，预计Orgo将在12个月内上涨至9.09%(可能上涨9.09%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Organogenesis Hldgs (ORGO)?
有机生成Hldgs(Orgo)的最新分析师评级是多少？
The latest analyst rating for Organogenesis Hldgs (NASDAQ: ORGO) was provided by Morgan Stanley, and Organogenesis Hldgs maintained their equal-weight rating.
有机生成类Hldgs(纳斯达克代码：ORGO)的最新分析师评级由摩根士丹利提供，有机生成类Hldgs维持同等权重评级。
When is the next analyst rating going to be posted or updated for Organogenesis Hldgs (ORGO)?
器官生成Hldgs(Orgo)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organogenesis Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organogenesis Hldgs was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与有机生成Hldgs的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。器官发生Hldgs的上一次评级是在2023年8月11日提交的，所以你应该预计下一次评级将在2024年8月11日左右提供。
Is the Analyst Rating Organogenesis Hldgs (ORGO) correct?
分析师对有机生成Hldgs(Orgo)的评级正确吗？
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a maintained with a price target of $5.00 to $3.00. The current price Organogenesis Hldgs (ORGO) is trading at is $2.75, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的有机生成Hldgs(Orgo)评级保持不变，目标价在5.00美元至3.00美元之间。ORGO目前的交易价格为2.75美元，超出了分析师的预测区间。